Comment on CMS-2026-1255-0001

Summary: Johnson & Johnson Services, Inc. supports the proposed rule, noting that it will improve transparency and patient access to medications by requiring electronic prior authorization and clearer denial justifications. The company also advocates for specific reforms, including prohibiting "embedded step therapy" and clarifying "date of service" policies for laboratory testing to prevent administrative denials.